In conclusion, the results presented here demonstrate that dual inhibition of EGFR with erlotinib and cetuximab, combined with the VEGF antibody bevacizumab, is well-tolerated, allowing full doses of all three drugs in patients with colorectal cancer. Here, EGFR is linked to colorectal cancer.